Navigation Links
Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder

- Findings Published in the British Journal of Hematology -

FREMONT, Calif., April 24 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML) today reported findings from an Ohio State University (OSU) clinical study that indicated that a surface-enhanced laser desorption/ionization time of flight (SELDI-TOF)-based thrombotic thrombocytopenic purpura (TTP) diagnostic test could be used to help estimate the risk of TTP relapses during clinical remission. OSU currently offers the TTP test as a laboratory developed test, based on an exclusive licensing agreement with Vermillion, and for which Vermillion sells OSU supplies and laboratory reagents.

The data -- published recently in the online edition of the British Journal of Haematology -- indicate that use of the test may provide a novel screening strategy to identify patients who may benefit from prophylactic treatment to help prevent relapse of this serious blood disorder. TTP is caused by a deficient activity of the enzyme ADAMTS13, which leads to platelet clumping, red blood cell destruction, and, in serious cases, to neurological abnormalities and renal failure.

"TTP is a life-threatening disease that affects thousands of people each year. The disease is characterized by frequent recurrences, with approximately half of all patients experiencing relapses," said Haifeng M. Wu, M.D., lead investigator of the study and Assistant Professor of Pathology and Medicine and Director of the Clinical Coagulation Laboratory at OSU Medical Center. "The SELDI-TOF technology was instrumental in improving sensitivity for extremely low levels of ADAMTS13, which may be used to help identify patients who could be candidates for prophylactic treatment based upon their increased risk for relapse of this devastating blood disorder."

The study showed that extremely low levels of ADAMTS13 activity are associated with increased risk of TTP relapses during remission. A key characteristic of the assay is that it is more sensitive than other assays and exhibits improved accuracy at low (<2.5 percent) ADAMTS13 activity.

"These study findings represent an important milestone, as they demonstrate that the test -- which our Company co-developed with the OSU Research Foundation -- could be utilized not only for diagnosing TTP, but also for surveillance of TTP patients during clinical remission," said Gail Page, President and CEO of Vermillion. "Vermillion is dedicated to the development and commercialization of molecular diagnostic tests to help physicians and their patients diagnose and appropriately treat diseases, particularly cardiovascular disease and cancer. The TTP test is an example of how our technology has led to significant new means to properly diagnose and screen patients with this serious disorder."

Using the SELDI-TOF technology, the TTP test could help physicians make the correct diagnosis, initiate timely treatment, and evaluate response to therapy. These new study findings suggest that the test can additionally be used to help screen for the risk of relapse in patients with TTP.

About the Study

ADAMTS13 activity and ADAMTS13 antibody (IgG) were evaluated in 157 clinical samples collected prospectively during periods of clinical remission from 24 TTP patients enrolled in other prospective studies at OSU. These patients received regular follow-up for an average of 23 months, with serial samples taken at 3-month intervals. Nine episodes of TTP relapse occurred among six patients. Logistic regression modeling was used to define the relationship between ADAMTS13 activity levels and the probability of TTP relapses.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at

Forward Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward- looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize TTP diagnostic products in 2008 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize TTP diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify new protein biomarkers and use such information to develop TTP diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its TTP diagnostic products; (5) uncertainty of market acceptance of its TTP diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; and (6) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
2. Vermillion Receives Award From the Society of Gynecologic Oncologists
3. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
7. SuperGens MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
8. Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges
9. Wayne State University and Oakwood Partner in New Device to Combat Congestive Heart Failure
10. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... nuevo enfoque combina la inmunoterapia con la terapia fotodinámica ... Clinical Cancer Research . --> Clinical ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... Avid collector, Andrew ... Arbor Michigan boxing style concert posters. This is one of Joplin's most famous and ... House at the University of Michigan in Ann Arbor. The According to Hawley, "It ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
(Date:11/26/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk based ... efficiency and reliability. , The new Q-Suite 6 platform is based on the latest ... itself into a specific piece of software for many key components of the suite. ...
Breaking Medicine News(10 mins):